Italian startup Plumestars has announced via Twitter that it has received orphan drug status from the EMA for its amikacin dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients.
Here am amazing news: we got the orphan drug designation for our Amikacin dry powder! http://t.co/Ag3rCnXZAz
— PlumeStars (@PlumeStars) December 21, 2014
According to the company’s website, it is also developing a tobramycin DPI.
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
